COMPUGROUP MEDICAL SE & CO K (COP.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:COP - DE000A288904 - Common Stock
22.66 EUR
+0.24 (+1.07%)
We assign a fundamental rating of 3 out of 10 to COP. COP was compared to 10 industry peers in the Health Care Technology industry. While COP is still in line with the averages on profitability rating, there are concerns on its financial health. While showing a medium growth rate, COP is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year COP was profitable.
COP had a positive operating cash flow in the past year.
In the past 5 years COP has always been profitable.
COP had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of COP (1.34%) is comparable to the rest of the industry.
COP has a Return On Equity of 4.15%. This is comparable to the rest of the industry: COP outperforms 50.00% of its industry peers.
Looking at the Return On Invested Capital, with a value of 3.53%, COP is doing worse than 60.00% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for COP is below the industry average of 8.41%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.34% | ||
| ROE | 4.15% | ||
| ROIC | 3.53% |
ROA(3y)2.65%
ROA(5y)3.3%
ROE(3y)7.71%
ROE(5y)9.17%
ROIC(3y)4.07%
ROIC(5y)4.45%
1.3 Margins
The Profit Margin of COP (2.34%) is comparable to the rest of the industry.
In the last couple of years the Profit Margin of COP has declined.
COP has a Operating Margin of 8.13%. This is comparable to the rest of the industry: COP outperforms 60.00% of its industry peers.
In the last couple of years the Operating Margin of COP has declined.
The Gross Margin of COP (83.85%) is better than 70.00% of its industry peers.
COP's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.13% | ||
| PM (TTM) | 2.34% | ||
| GM | 83.85% |
OM growth 3Y-2.61%
OM growth 5Y-10.29%
PM growth 3Y-23.61%
PM growth 5Y-19.42%
GM growth 3Y32.01%
GM growth 5Y16.44%
2. Health
2.1 Basic Checks
COP has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, COP has less shares outstanding
Compared to 5 years ago, COP has more shares outstanding
COP has a worse debt/assets ratio than last year.
2.2 Solvency
COP has an Altman-Z score of 1.79. This is a bad value and indicates that COP is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of COP (1.79) is comparable to the rest of the industry.
The Debt to FCF ratio of COP is 9.74, which is on the high side as it means it would take COP, 9.74 years of fcf income to pay off all of its debts.
COP has a Debt to FCF ratio (9.74) which is comparable to the rest of the industry.
A Debt/Equity ratio of 1.22 is on the high side and indicates that COP has dependencies on debt financing.
COP's Debt to Equity ratio of 1.22 is on the low side compared to the rest of the industry. COP is outperformed by 80.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.22 | ||
| Debt/FCF | 9.74 | ||
| Altman-Z | 1.79 |
ROIC/WACC0.67
WACC5.27%
2.3 Liquidity
COP has a Current Ratio of 1.12. This is a normal value and indicates that COP is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of COP (1.12) is worse than 60.00% of its industry peers.
A Quick Ratio of 1.09 indicates that COP should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.09, COP is doing worse than 60.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.12 | ||
| Quick Ratio | 1.09 |
3. Growth
3.1 Past
COP shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -45.71%.
Measured over the past years, COP shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -13.58% on average per year.
The Revenue has decreased by -2.19% in the past year.
The Revenue has been growing by 9.12% on average over the past years. This is quite good.
EPS 1Y (TTM)-45.71%
EPS 3Y-20.77%
EPS 5Y-13.58%
EPS Q2Q%-40%
Revenue 1Y (TTM)-2.19%
Revenue growth 3Y4.02%
Revenue growth 5Y9.12%
Sales Q2Q%0.54%
3.2 Future
Based on estimates for the next years, COP will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.19% on average per year.
The Revenue is expected to grow by 0.36% on average over the next years.
EPS Next Y1.4%
EPS Next 2Y4.91%
EPS Next 3Y9.19%
EPS Next 5YN/A
Revenue Next Year2.47%
Revenue Next 2Y2.65%
Revenue Next 3Y2.49%
Revenue Next 5Y0.36%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 43.58 indicates a quite expensive valuation of COP.
COP's Price/Earnings ratio is in line with the industry average.
Compared to an average S&P500 Price/Earnings ratio of 27.25, COP is valued quite expensively.
COP is valuated correctly with a Price/Forward Earnings ratio of 12.88.
70.00% of the companies in the same industry are more expensive than COP, based on the Price/Forward Earnings ratio.
COP is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 23.98, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 43.58 | ||
| Fwd PE | 12.88 |
4.2 Price Multiples
70.00% of the companies in the same industry are more expensive than COP, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, COP is valued a bit cheaper than 80.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14.34 | ||
| EV/EBITDA | 9.24 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
PEG (NY)31.03
PEG (5Y)N/A
EPS Next 2Y4.91%
EPS Next 3Y9.19%
5. Dividend
5.1 Amount
COP has a yearly dividend return of 0.22%, which is pretty low.
Compared to an average industry Dividend Yield of 1.99, COP has a dividend in line with its industry peers.
Compared to an average S&P500 Dividend Yield of 1.92, COP's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.22% |
5.2 History
The dividend of COP is nicely growing with an annual growth rate of 14.75%!
Dividend Growth(5Y)14.75%
Div Incr Years2
Div Non Decr Years3
5.3 Sustainability
191.63% of the earnings are spent on dividend by COP. This is not a sustainable payout ratio.
The dividend of COP is growing, but the earnings are growing slower. This means the dividend growth is not sustainable.
DP191.63%
EPS Next 2Y4.91%
EPS Next 3Y9.19%
FRA:COP (6/24/2025, 7:00:00 PM)
22.66
+0.24 (+1.07%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners13.38%
Inst Owner ChangeN/A
Ins Owners53.51%
Ins Owner ChangeN/A
Market Cap1.22B
Revenue(TTM)1.16B
Net Income(TTM)27.00M
Analysts56.67
Price Target21.32 (-5.91%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.22% |
Yearly Dividend1
Dividend Growth(5Y)14.75%
DP191.63%
Div Incr Years2
Div Non Decr Years3
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 43.58 | ||
| Fwd PE | 12.88 | ||
| P/S | 1.05 | ||
| P/FCF | 14.34 | ||
| P/OCF | 8.46 | ||
| P/B | 1.87 | ||
| P/tB | N/A | ||
| EV/EBITDA | 9.24 |
EPS(TTM)0.52
EY2.29%
EPS(NY)1.76
Fwd EY7.76%
FCF(TTM)1.58
FCFY6.97%
OCF(TTM)2.68
OCFY11.82%
SpS21.51
BVpS12.12
TBVpS-12.86
PEG (NY)31.03
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.34% | ||
| ROE | 4.15% | ||
| ROCE | 5.85% | ||
| ROIC | 3.53% | ||
| ROICexc | 3.83% | ||
| ROICexgc | 41.76% | ||
| OM | 8.13% | ||
| PM (TTM) | 2.34% | ||
| GM | 83.85% | ||
| FCFM | 7.35% |
ROA(3y)2.65%
ROA(5y)3.3%
ROE(3y)7.71%
ROE(5y)9.17%
ROIC(3y)4.07%
ROIC(5y)4.45%
ROICexc(3y)4.31%
ROICexc(5y)4.74%
ROICexgc(3y)36.56%
ROICexgc(5y)51.39%
ROCE(3y)6.74%
ROCE(5y)7.38%
ROICexgc growth 3Y-23.91%
ROICexgc growth 5Y-9.04%
ROICexc growth 3Y-4.3%
ROICexc growth 5Y-14.26%
OM growth 3Y-2.61%
OM growth 5Y-10.29%
PM growth 3Y-23.61%
PM growth 5Y-19.42%
GM growth 3Y32.01%
GM growth 5Y16.44%
F-Score6
Asset Turnover0.57
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.22 | ||
| Debt/FCF | 9.74 | ||
| Debt/EBITDA | 3.86 | ||
| Cap/Depr | 52.61% | ||
| Cap/Sales | 5.11% | ||
| Interest Coverage | 2.54 | ||
| Cash Conversion | 69.81% | ||
| Profit Quality | 314.42% | ||
| Current Ratio | 1.12 | ||
| Quick Ratio | 1.09 | ||
| Altman-Z | 1.79 |
F-Score6
WACC5.27%
ROIC/WACC0.67
Cap/Depr(3y)60.99%
Cap/Depr(5y)64.22%
Cap/Sales(3y)5.98%
Cap/Sales(5y)6.31%
Profit Quality(3y)175.79%
Profit Quality(5y)158.42%
High Growth Momentum
Growth
EPS 1Y (TTM)-45.71%
EPS 3Y-20.77%
EPS 5Y-13.58%
EPS Q2Q%-40%
EPS Next Y1.4%
EPS Next 2Y4.91%
EPS Next 3Y9.19%
EPS Next 5YN/A
Revenue 1Y (TTM)-2.19%
Revenue growth 3Y4.02%
Revenue growth 5Y9.12%
Sales Q2Q%0.54%
Revenue Next Year2.47%
Revenue Next 2Y2.65%
Revenue Next 3Y2.49%
Revenue Next 5Y0.36%
EBIT growth 1Y-18.88%
EBIT growth 3Y1.31%
EBIT growth 5Y-2.11%
EBIT Next Year77.58%
EBIT Next 3Y24.98%
EBIT Next 5Y17.79%
FCF growth 1Y3.01%
FCF growth 3Y-11.08%
FCF growth 5Y-0.24%
OCF growth 1Y-8.49%
OCF growth 3Y-7.96%
OCF growth 5Y3.13%
COMPUGROUP MEDICAL SE & CO K / COP.DE FAQ
What is the ChartMill fundamental rating of COMPUGROUP MEDICAL SE & CO K (COP.DE) stock?
ChartMill assigns a fundamental rating of 3 / 10 to COP.DE.
Can you provide the valuation status for COMPUGROUP MEDICAL SE & CO K?
ChartMill assigns a valuation rating of 3 / 10 to COMPUGROUP MEDICAL SE & CO K (COP.DE). This can be considered as Overvalued.
How profitable is COMPUGROUP MEDICAL SE & CO K (COP.DE) stock?
COMPUGROUP MEDICAL SE & CO K (COP.DE) has a profitability rating of 4 / 10.
What is the earnings growth outlook for COMPUGROUP MEDICAL SE & CO K?
The Earnings per Share (EPS) of COMPUGROUP MEDICAL SE & CO K (COP.DE) is expected to grow by 1.4% in the next year.
Can you provide the dividend sustainability for COP stock?
The dividend rating of COMPUGROUP MEDICAL SE & CO K (COP.DE) is 2 / 10 and the dividend payout ratio is 191.63%.